#Migraine and #Yawning
http://onlinelibrary.wiley.com/doi/10.1111/head.13195/abstract
One hundred and fifty-four patients reported repetitive yawning (45.4%) during migraine attacks. Repetitive yawning was reported in the 11.2% of the patients in the premonitory phase, 24.2% during headaches, and 10% both in the premonitory phase and during headaches. Migraine with aura (46.8 vs 31.9%; P = .005), accompanying nausea (89.6 vs 75.1%; P = .001), vomiting (48.7 vs 37.8%; P = .044), osmophobia (66.7 vs 52.3%; P = .024), and cutaneous allodynia (58.2 vs 46%; P = .032) were more common in patients with yawning than without. Other dopaminergic-hypothalamic premonitory symptoms (41.6 vs 26.5%; P = .003), especially sleepiness (17.5 vs 5.9%; P = .001), irritability/anxiety (21.4% vs 11.4%; P = .019), nausea/vomiting (10.4 vs 4.3%; P = .03), and changes in appetite (18.2 vs 9.7%; P = .024), were also more frequent in patients with yawning than without. After being adjusted for all other relevant covariates, the odds of repetitive yawning were increased by the presence of nausea (OR 2.88; 95% CI 1.453-5.726; P = .002) and migraine with aura (OR 1.66; 95% CI 1.035-2.671; P = .036).
Conclusions
Our results demonstrated that yawning is a common self-reported symptom leading or accompanying migraine attacks and is associated with aura, nausea and/or vomiting, osmophobia, and cutaneous allodynia in patients with migraine. Although yawning is a rather frequently seen behavior, it is a unique and reliable symptom in patients with migraine that may offer an opportunity for early treatment of migraine attacks
http://onlinelibrary.wiley.com/doi/10.1111/head.13195/abstract
One hundred and fifty-four patients reported repetitive yawning (45.4%) during migraine attacks. Repetitive yawning was reported in the 11.2% of the patients in the premonitory phase, 24.2% during headaches, and 10% both in the premonitory phase and during headaches. Migraine with aura (46.8 vs 31.9%; P = .005), accompanying nausea (89.6 vs 75.1%; P = .001), vomiting (48.7 vs 37.8%; P = .044), osmophobia (66.7 vs 52.3%; P = .024), and cutaneous allodynia (58.2 vs 46%; P = .032) were more common in patients with yawning than without. Other dopaminergic-hypothalamic premonitory symptoms (41.6 vs 26.5%; P = .003), especially sleepiness (17.5 vs 5.9%; P = .001), irritability/anxiety (21.4% vs 11.4%; P = .019), nausea/vomiting (10.4 vs 4.3%; P = .03), and changes in appetite (18.2 vs 9.7%; P = .024), were also more frequent in patients with yawning than without. After being adjusted for all other relevant covariates, the odds of repetitive yawning were increased by the presence of nausea (OR 2.88; 95% CI 1.453-5.726; P = .002) and migraine with aura (OR 1.66; 95% CI 1.035-2.671; P = .036).
Conclusions
Our results demonstrated that yawning is a common self-reported symptom leading or accompanying migraine attacks and is associated with aura, nausea and/or vomiting, osmophobia, and cutaneous allodynia in patients with migraine. Although yawning is a rather frequently seen behavior, it is a unique and reliable symptom in patients with migraine that may offer an opportunity for early treatment of migraine attacks
#Migraine and risk of #cardiovascular diseases: Danish population based matched cohort study
http://www.bmj.com/content/360/bmj.k96
Correspondingly, migraine was positively associated with myocardial infarction (adjusted hazard ratio 1.49, 95% confidence interval 1.36 to 1.64), ischaemic stroke (2.26, 2.11 to 2.41), and haemorrhagic stroke (1.94, 1.68 to 2.23), as well as venous thromboembolism (1.59, 1.45 to 1.74) and atrial fibrillation or atrial flutter (1.25, 1.16 to 1.36). No meaningful association was found with peripheral artery disease (adjusted hazard ratio 1.12, 0.96 to 1.30) or heart failure (1.04, 0.93 to 1.16). The associations, particularly for stroke outcomes, were stronger during the short term (0-1 years) after diagnosis than the long term (up to 19 years), in patients with aura than in those without aura, and in women than in men. In a subcohort of patients, the associations persisted after additional multivariable adjustment for body mass index and smoking.
Conclusions Migraine was associated with increased risks of myocardial infarction, ischaemic stroke, haemorrhagic stroke, venous thromboembolism, and atrial fibrillation or atrial flutter. Migraine may be an important risk factor for most cardiovascular diseases
http://www.bmj.com/content/360/bmj.k96
Correspondingly, migraine was positively associated with myocardial infarction (adjusted hazard ratio 1.49, 95% confidence interval 1.36 to 1.64), ischaemic stroke (2.26, 2.11 to 2.41), and haemorrhagic stroke (1.94, 1.68 to 2.23), as well as venous thromboembolism (1.59, 1.45 to 1.74) and atrial fibrillation or atrial flutter (1.25, 1.16 to 1.36). No meaningful association was found with peripheral artery disease (adjusted hazard ratio 1.12, 0.96 to 1.30) or heart failure (1.04, 0.93 to 1.16). The associations, particularly for stroke outcomes, were stronger during the short term (0-1 years) after diagnosis than the long term (up to 19 years), in patients with aura than in those without aura, and in women than in men. In a subcohort of patients, the associations persisted after additional multivariable adjustment for body mass index and smoking.
Conclusions Migraine was associated with increased risks of myocardial infarction, ischaemic stroke, haemorrhagic stroke, venous thromboembolism, and atrial fibrillation or atrial flutter. Migraine may be an important risk factor for most cardiovascular diseases
!!
Efficacy and tolerability of #erenumab in patients with episodic #migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32534-0/fulltext
Between March 20, 2017, and Oct 27, 2017, 246 participants were randomly assigned, 121 to the erenumab group and 125 to the placebo group. 95 of 246 (39%) participants had previously unsuccessfully tried two preventive drugs, 93 (38%) had tried three, and 56 (23%) had tried four. At week 12, 36 (30%) patients in the erenumab had a 50% or greater reduction from baseline in the mean number of monthly migraine days, compared with 17 (14%) in the placebo group (odds ratio 2·7 95% CI 1·4–5·2; p=0·002). The tolerability and safety profiles of erenumab and placebo were similar. The most frequent treatment-emergent adverse event was injection site pain, which occurred in seven (6%) participants in both groups.
Interpretation
Compared with placebo, erenumab was efficacious in patients with episodic migraine who previously did not respond to or tolerate between two and four previous migraine preventive treatments. Erenumab might be an option for patients with difficult-to-treat migraine who have high unmet needs and few treatment options
Efficacy and tolerability of #erenumab in patients with episodic #migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32534-0/fulltext
Between March 20, 2017, and Oct 27, 2017, 246 participants were randomly assigned, 121 to the erenumab group and 125 to the placebo group. 95 of 246 (39%) participants had previously unsuccessfully tried two preventive drugs, 93 (38%) had tried three, and 56 (23%) had tried four. At week 12, 36 (30%) patients in the erenumab had a 50% or greater reduction from baseline in the mean number of monthly migraine days, compared with 17 (14%) in the placebo group (odds ratio 2·7 95% CI 1·4–5·2; p=0·002). The tolerability and safety profiles of erenumab and placebo were similar. The most frequent treatment-emergent adverse event was injection site pain, which occurred in seven (6%) participants in both groups.
Interpretation
Compared with placebo, erenumab was efficacious in patients with episodic migraine who previously did not respond to or tolerate between two and four previous migraine preventive treatments. Erenumab might be an option for patients with difficult-to-treat migraine who have high unmet needs and few treatment options
!!
Association Between Dry #Eye Disease and #Migraine Headaches in a Large Population-Based Study
https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2726703
The base population consisted of 72 969 patients, including 41 764 men (57.2%) and 31 205 women (42.8%). Of these, 5352 patients (7.3%) carried a diagnosis of migraine headache, and 9638 (13.2%) carried a diagnosis of DED. The odds of having DED given a diagnosis of migraine headaches was 1.72 (95% CI, 1.60-1.85) times higher than that of patients without migraine headaches. After accounting for multiple confounding factors, the odds of having DED given a diagnosis of migraine headaches was 1.42 (95% CI, 1.20-1.68) times higher than that of patients without migraine headaches.
Conclusions and Relevance These findings suggest that patients with migraine headaches are more likely to have comorbid DED compared with the general population. Although this association may not reflect cause and effect if unidentified confounders account for the results, these data suggest that patients with migraine headaches may be at risk of carrying a comorbid diagnosis of DED.
Association Between Dry #Eye Disease and #Migraine Headaches in a Large Population-Based Study
https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2726703
The base population consisted of 72 969 patients, including 41 764 men (57.2%) and 31 205 women (42.8%). Of these, 5352 patients (7.3%) carried a diagnosis of migraine headache, and 9638 (13.2%) carried a diagnosis of DED. The odds of having DED given a diagnosis of migraine headaches was 1.72 (95% CI, 1.60-1.85) times higher than that of patients without migraine headaches. After accounting for multiple confounding factors, the odds of having DED given a diagnosis of migraine headaches was 1.42 (95% CI, 1.20-1.68) times higher than that of patients without migraine headaches.
Conclusions and Relevance These findings suggest that patients with migraine headaches are more likely to have comorbid DED compared with the general population. Although this association may not reflect cause and effect if unidentified confounders account for the results, these data suggest that patients with migraine headaches may be at risk of carrying a comorbid diagnosis of DED.
Jamanetwork
Association Between Dry Eye Disease and Migraine Headaches
This population-based case-control study assesses the strength of an association between dry eye disease and migraine headaches among patients treated in health care facilities affiliated with a university health system.
!!
Nightly #sleep duration, fragmentation, and quality and daily risk of #migraine
..migraine onset on the day immediately following the sleep period (day 0) and the following day (day 1).
..Sleep duration ≤6.5 hours and poor sleep quality were not associated with migraine on day 0 or day 1. Diary-reported low efficiency was associated with 39% higher odds of headache on day 1 (odds ratio [OR] 1.39, 95% confidence interval [CI] 1.06–1.81). Actigraphic-assessed high fragmentation was associated with lower odds of migraine on day 0 (wake after sleep onset >53 minutes, OR 0.64, 95% CI 0.48–0.86; efficiency ≤88%, OR 0.74, 95% CI 0.56–0.99).
Conclusion Short sleep duration and low sleep quality were not temporally associated with migraine. Sleep fragmentation, defined by low sleep efficiency, was associated with higher odds of migraine on day 1. Further research is needed to understand the clinical and neurobiologic implications of sleep fragmentation and risk of migraine.
https://bit.ly/2FeiHLB
Nightly #sleep duration, fragmentation, and quality and daily risk of #migraine
..migraine onset on the day immediately following the sleep period (day 0) and the following day (day 1).
..Sleep duration ≤6.5 hours and poor sleep quality were not associated with migraine on day 0 or day 1. Diary-reported low efficiency was associated with 39% higher odds of headache on day 1 (odds ratio [OR] 1.39, 95% confidence interval [CI] 1.06–1.81). Actigraphic-assessed high fragmentation was associated with lower odds of migraine on day 0 (wake after sleep onset >53 minutes, OR 0.64, 95% CI 0.48–0.86; efficiency ≤88%, OR 0.74, 95% CI 0.56–0.99).
Conclusion Short sleep duration and low sleep quality were not temporally associated with migraine. Sleep fragmentation, defined by low sleep efficiency, was associated with higher odds of migraine on day 1. Further research is needed to understand the clinical and neurobiologic implications of sleep fragmentation and risk of migraine.
https://bit.ly/2FeiHLB
Neurology
Nightly sleep duration, fragmentation, and quality and daily risk of migraine
Objective To test the hypotheses that insufficient duration, high fragmentation, and poor sleep quality are temporally associated with migraine onset on the day immediately following the sleep period (day 0) and the following day (day 1).
Methods In this…
Methods In this…
#Migraine, obesity and body #fat distribution – a population-based study
https://2medical.news/2020/08/23/migraine-obesity-and-body-fat-distribution-a-population-based-study/
Obesity has been linked to an increased prevalence of migraine, and to increased migraine attack frequency, but several questions are left unanswered by previous studies. We examined the relationship between obesity and headache in a large, population-based study where we could take into account body fat distribution, migraine subtypes and tension-type headache.. ..Both total body obesity (TBO) and abdominal obesity (AO) were associated with a …
https://2medical.news/2020/08/23/migraine-obesity-and-body-fat-distribution-a-population-based-study/
Obesity has been linked to an increased prevalence of migraine, and to increased migraine attack frequency, but several questions are left unanswered by previous studies. We examined the relationship between obesity and headache in a large, population-based study where we could take into account body fat distribution, migraine subtypes and tension-type headache.. ..Both total body obesity (TBO) and abdominal obesity (AO) were associated with a …
Evaluation of #green light exposure on #headache frequency and quality of life in #migraine patients: A preliminary one-way cross-over clinical trial
https://2medical.news/2020/10/04/evaluation-of-green-light-exposure-on-headache-frequency-and-quality-of-life-in-migraine-patients-a-preliminary-one-way-cross-over-clinical-trial/
..We recruited (29 total) patients, of whom seven had episodic migraine and 22 had chronic migraine. We used a one-way cross-over design consisting of exposure for 1–2 hours daily to white light emitting diodes for 10 weeks, followed by a 2-week washout period followed by exposure for 1–2 hours daily to green light emitting diodes for 10 weeks. Patients were allowed to continue current therapies …
https://2medical.news/2020/10/04/evaluation-of-green-light-exposure-on-headache-frequency-and-quality-of-life-in-migraine-patients-a-preliminary-one-way-cross-over-clinical-trial/
..We recruited (29 total) patients, of whom seven had episodic migraine and 22 had chronic migraine. We used a one-way cross-over design consisting of exposure for 1–2 hours daily to white light emitting diodes for 10 weeks, followed by a 2-week washout period followed by exposure for 1–2 hours daily to green light emitting diodes for 10 weeks. Patients were allowed to continue current therapies …
Simultaneous Comparisons of 25 Acute #Migraine Medications Based on 10 Million Users’ Self-Reported Records From a Smartphone Application
https://2medical.news/2023/12/13/simultaneous-comparisons-of-25-acute-migraine-medications-based-on-10-million-users-self-reported-records-from-a-smartphone-application/
https://2medical.news/2023/12/13/simultaneous-comparisons-of-25-acute-migraine-medications-based-on-10-million-users-self-reported-records-from-a-smartphone-application/
2Medical.News
Simultaneous Comparisons of 25 Acute #Migraine Medications Based on 10 Million Users’ Self-Reported Records From a Smartphone Application
Many acute treatment options exist for migraine. However, large-scale, head-to-head comparisons of treatment effectiveness from real-world patient experience reports are lacking.MethodsThis is a re…
#Migraine is associated with the development of adult patients with inflammatory #bowel disease: a nationwide, population-based study
https://2medical.news/2024/02/01/migraine-is-associated-with-the-development-of-adult-patients-with-inflammatory-bowel-disease-a-nationwide-population-based-study/
https://2medical.news/2024/02/01/migraine-is-associated-with-the-development-of-adult-patients-with-inflammatory-bowel-disease-a-nationwide-population-based-study/
2Medical.News
#Migraine is associated with the development of adult patients with inflammatory #bowel disease: a nationwide, population-based…
It has been reported that migraine is more common in patients with inflammatory bowel disease (IBD) than in general. However, the impact of migraine on the development of IBD has not yet been eluci…
Early Use of #Erenumab vs Nonspecific Oral #Migraine PreventivesThe APPRAISE Randomized Clinical Trial
https://2medical.news/2024/04/03/early-use-of-erenumab-vs-nonspecific-oral-migraine-preventivesthe-appraise-randomized-clinical-trial/
https://2medical.news/2024/04/03/early-use-of-erenumab-vs-nonspecific-oral-migraine-preventivesthe-appraise-randomized-clinical-trial/
2Medical.News
Early Use of #Erenumab vs Nonspecific Oral #Migraine PreventivesThe APPRAISE Randomized Clinical Trial
Importance Patients with migraine often cycle through multiple nonspecific preventive medications due to poor tolerability and/or inadequate efficacy leading to low adherence and increased disease…
Use of #Acid-Suppression Therapy and Odds of #Migraine and Severe Headache in the National Health and Nutrition Examination Survey
https://2medical.news/2024/04/27/use-of-acid-suppression-therapy-and-odds-of-migraine-and-severe-headache-in-the-national-health-and-nutrition-examination-survey/
https://2medical.news/2024/04/27/use-of-acid-suppression-therapy-and-odds-of-migraine-and-severe-headache-in-the-national-health-and-nutrition-examination-survey/
2Medical.News
Use of #Acid-Suppression Therapy and Odds of #Migraine and Severe Headache in the National Health and Nutrition Examination Survey
Headache is an adverse event associated with the use of proton pump inhibitors (PPIs). Recently, migraine has emerged more specifically as a potential adverse event with PPI use. The objectives of …
Efficacy of #Atogepant in Chronic #Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial
https://2medical.news/2024/08/05/efficacy-of-atogepant-in-chronic-migraine-with-and-without-acute-medication-overuse-in-the-randomized-double-blind-phase-3-progress-trial/
https://2medical.news/2024/08/05/efficacy-of-atogepant-in-chronic-migraine-with-and-without-acute-medication-overuse-in-the-randomized-double-blind-phase-3-progress-trial/
2Medical.News
Efficacy of #Atogepant in Chronic #Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3…
AbstractBackground and ObjectivesAtogepant is an oral, calcitonin gene-related peptide receptor antagonist approved for the preventive treatment of migraine. We evaluated the efficacy of atogepant …